Recruiting

NECTARCryotechnology for Pancreatic Necrosis

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Cryotechnology Necrosectomy Procedure

Device
Who is being recruted

Digestive System Diseases+4

+ Necrosis

+ Pancreatic Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: January 2026
See protocol details

Summary

Principal SponsorChristopher C. Thompson, MD, MSc
Study ContactMichele Ryan, MSMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 1, 2026

Actual date on which the first participant was enrolled.

Acute pancreatitis is a common and serious condition that sometimes leads to pancreatic necrosis, where parts of the pancreas die. This study focuses on improving the treatment for pancreatic necrosis, which can be life-threatening and difficult to manage with existing methods. Traditional treatments like surgery carry high risks, and other less invasive options may not effectively remove all the dead tissue, often requiring multiple procedures. This study is exploring the use of cryotechnology, which involves using extremely cold temperatures to remove tissue, as a potentially safer and more effective method to treat pancreatic necrosis. In this study, participants with pancreatic necrosis will undergo a procedure using cryoprobes, which are special instruments that use cold temperatures to remove dead pancreatic tissue. The process is minimally invasive and performed through endoscopic techniques. The study aims to measure how well cryotechnology works in safely removing necrotic tissue and whether it reduces the need for multiple procedures. Researchers are particularly interested in its ability to obtain larger tissue samples without causing significant bleeding, which could make it a better option for managing this serious condition.

Official TitleNecrosectomy With Cryotechnology for Accelerated Removal
NCT06553651
Principal SponsorChristopher C. Thompson, MD, MSc
Study ContactMichele Ryan, MSMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Digestive System DiseasesNecrosisPancreatic DiseasesPancreatitisPathologic ProcessesPathological Conditions, Signs and SymptomsPancreatitis, Acute Necrotizing

Criteria

Inclusion Criteria: * Subjects aged 18 years and above, inclusive of both males and females. * Patients with symptomatic pancreatic necrosis resulting from acute pancreatitis, indicated for endoscopic necrosectomy following endoscopic ultrasound (EUS)-guided drainage. * Imaging indicative of ≥30% necrotic material within the pancreas. * Walled-off pancreatic necrosis (WOPN) size ≥6 cm. * Subjects able to tolerate repeated endoscopic procedures. * Capacity for providing informed consent. * Understanding of study requirements, provision of written informed consent, and willingness and ability to attend required follow-up assessments through 21 (+/- 7) days. Exclusion Criteria: * Inability to provide informed consent. * Unwillingness to undergo repeated endoscopies. * Presence of documented Pseudoaneurysm \> 1cm within the WOPN. * Intervening gastric varices or unavoidable blood vessels within the access tract. * Use of dual antiplatelet therapy or therapeutic anticoagulation that cannot be temporarily discontinued. * Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure. * Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential. * Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Enrolled subjects will undergo direct endoscopic necrosectomy using 1.7 mm single use, flexible cryoprobes, aimed at effectively removing necrotic tissue within the pancreatic cavity.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Brigham and Women's Hospital

Boston, United StatesOpen Brigham and Women's Hospital in Google Maps
Recruiting
One Study Center